Trillium Therapeutics

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Pfizer

Pfizer Inc (NYSE: PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion. The offer price represents a 118% premium to the 60-day weighted average price for Trillium.

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

The shares of Trillium Therapeutics Inc (NASDAQ: TRIL) increased by over 190% pre-market. This is why it happened.

Trillium Therapeutics Shares Increase Over 190% Pre-Market: Why It Happened

Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.

Trillium Therapeutics shares soar on Pfizer's $2.26B deal

Shares of Trillium Therapeutics Inc. TRIL, +3.92% nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an agreement to be acquired by Pfizer Inc. PFE, -0.16% in a cash deal valued $2.26 billion. Under terms of the agreement, Pfizer will pay $18.50 for each Trillium share it doesn't already own, which is 203.8% above Friday's closing price of $6.09.

Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion

Pfizer Inc said on Monday it would buy shares of Trillium Therapeutics Inc that it does not already own in a deal that values the cancer drugs maker at $2.26 billion.

Pfizer to buy Trillium Therapeutics in $2.26 billion deal

CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.

Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

Pacific Biosciences of California

Teladoc

These companies could upend the industry in the years ahead.

$5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years

Wall Street's short attention span has created an attractive entry point in this once-loved biotech.

This Biotech Stock Is Too Cheap to Ignore

CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000® and 3000® Indices effective after the US market opens on June 28.

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 8, 2021.

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

Trillium recently provided an update on its clinical trials. New data continues to show a strong response as a monotherapy in a heavily pre-treated patient population.

Trillium Therapeutics: Recent Data Update Solidifies Its Approach

CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.

Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including three new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure at the American Society of Hematology 2020 Annual Meeting.

Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a data update, announced Phase 1b/2 program priorities across seven hematologic and solid tumor indications, and reported governance changes with its Board of Directors.

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

Axsome Therapeutics

Frequency Therapeutics

Their stocks have collapsed. But they could still be huge winners.

3 Biotech Stocks That Could Be Millionaire-Makers

Trillium is a leader in the CD47 inhibitor space in terms of data claims. Pfizer has recently taken an interest.

Trillium Therapeutics' CD47 Lead Evokes Pfizer's Interest

bluebird bio

SAGE Therapeutics

Though these stocks have dropped, upcoming news offers hope for them to rebound.

3 Top Biotech Stocks for Spring 2021

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its CD47 clinical programs, for the year ended December 31, 2020. All financial amounts in this news release are in United States dollars, unless otherwise stated.

Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?

Why the Market Is So Bullish About Trillium Therapeutics

Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incredibly crowded. There are 10+ groups developing a drug that hits the CD47 pathway.

Trillium Therapeutics: A Potentially Undervalued CD47 Player

Amgen

Illumina

Buy these three biotech stocks before they take off.

3 Top Biotech Picks for January

When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.

News for Trillium Therapeutics Stock (TRIL)